Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
oxaliplatin (eloxatin) (1 trial)
bortezomib (velcade) (1 trial)
melphalan (alkeran) (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Lung Neoplasms (Phase 2)
Trials (2 total)
Trial APIs (3 total)